Madrigal Pharmaceuticals, Inc. Common Stock
MDGL
$480.77
+1.37%
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with significant unmet medical need. The company is a pure-play biotech disruptor, having secured the first-ever FDA approval for a MASH drug with its oral therapy, Rezdiffra (resmetirom). The current investor narrative is dominated by the commercial launch trajectory of Rezdiffra, with intense focus on quarterly revenue ramp, market penetration, and competitive positioning as the first mover in a potentially multi-billion dollar market, balanced against ongoing debate about the drug's long-term uptake and profitability timeline.…
MDGL
Madrigal Pharmaceuticals, Inc. Common Stock
$480.77
Related headlines
Investment Opinion: Should I buy MDGL Today?
Rating: Hold. The core thesis is that while Madrigal's Rezdiffra launch is demonstrating impressive early success, the stock's elevated valuation and critical near-term cash burn create an asymmetric risk/reward profile that favors waiting for either clearer profitability signals or a more attractive entry point. This aligns with the limited but bullish analyst coverage which implies significant upside but also high uncertainty.
Supporting evidence includes the explosive 210.77% YoY revenue growth to $321.1M in Q4 2025, high gross margins of 92.39%, and a forward PE of 39.81x that prices in rapid earnings inflection. However, the trailing PS of 13.63x is elevated versus the biotech sector, the company is burning -$190M in TTM free cash flow, and net losses, while improving, remain substantial at -$58.6M last quarter. The stock trades 20% below its 52-week high, reflecting recent skepticism about its ability to fund growth.
The two biggest risks that could invalidate this Hold thesis are 1) a slowdown in quarterly sequential revenue growth below 10%, signaling market saturation, and 2) the announcement of a dilutive equity offering to address the cash shortfall. This Hold would upgrade to a Buy if the PS multiple compresses below 10x on sustained growth, or if the company demonstrates a clear quarter-over-quarter path to positive operating cash flow. It would downgrade to a Sell if quarterly revenue growth turns negative or if cash falls below $100M without a clear funding plan. The stock is currently fairly valued relative to its hyper-growth phase but overvalued on a fundamental profitability basis.
Sign up to view all
MDGL 12-Month Price Forecast
Madrigal is at a critical commercial inflection point with impressive early launch metrics but facing a tangible liquidity cliff. The neutral stance reflects the high probability (55%) base case of continued growth paired with a necessary capital raise, which should keep the stock range-bound. The confidence is medium due to the binary nature of biotech commercialization and the limited analyst dataset. The stance would upgrade to bullish on evidence of sustainable positive operating cash flow, which would de-risk the investment thesis. It would downgrade to bearish on any material slowdown in the quarterly revenue growth rate, which would simultaneously threaten the valuation multiple and accelerate the cash crisis.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Madrigal Pharmaceuticals, Inc. Common Stock's 12-month outlook, with a consensus price target around $625.00 and implied upside of +30.0% versus the current price.
Average Target
$625.00
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$385 - $625
Analyst target range
Analyst coverage is limited, with only 5 analysts providing estimates, which is typical for a commercial-stage biotech of this size. The consensus sentiment is bullish, with recent institutional ratings from firms like Piper Sandler ('Overweight'), B. Riley ('Buy'), and HC Wainwright ('Buy') indicating a positive outlook on the launch. The average revenue estimate for the forward period is approximately $4.97 billion, signaling massive growth expectations from the current ~$1.2 billion annualized run rate. The target price range implied by the EPS estimates ($55.16 to $70.62) and the current PS multiple suggests a wide dispersion of outcomes, reflecting high uncertainty around peak sales penetration, competitive dynamics, and the path to profitability. A wide target spread is common for a company at this inflection point, signaling that analyst conviction varies significantly based on assumptions about Rezdiffra's commercial success and future market share.
Bulls vs Bears: MDGL Investment Factors
The bull case, supported by explosive 211% YoY revenue growth and first-mover status in a massive market, currently holds stronger evidence due to the tangible success of the Rezdiffra launch. However, the bear case presents severe near-term financial risks, primarily the unsustainable cash burn of -$190M TTM against a cash balance of $204M. The single most important tension in the investment debate is the race between revenue scaling and cash depletion. If revenue growth continues to accelerate and operating losses narrow faster than expected, the path to profitability and capital independence becomes clear. If growth plateaus or cash burn persists, the company will be forced to raise dilutive capital, threatening shareholder value.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue of $321.1 million represents 210.77% year-over-year growth, demonstrating a successful commercial launch. Sequential quarterly revenue has grown consistently from $0 in Q1 2024 to $321.1 million in Q4 2025, confirming strong market uptake for Rezdiffra.
- First-Mover Advantage in Large Market: Rezdiffra is the first-ever FDA-approved therapy for MASH, a multi-billion dollar market with high unmet need. Analyst consensus expects forward revenue to reach ~$4.97 billion, indicating massive growth potential from the current ~$1.2 billion annualized run rate.
- Improving Operating Leverage: Net loss narrowed significantly from -$114.2 million in Q3 2025 to -$58.6 million in Q4 2025 as revenue scaled. Gross margins remain exceptionally high at 92.39%, providing a clear path to profitability as sales volume increases.
- Strong Balance Sheet Position: The company maintains a robust current ratio of 4.01 and a manageable debt-to-equity ratio of 0.59. This financial flexibility supports continued commercial investment without immediate solvency concerns.
Bearish
- Unsustainable Cash Burn: Trailing twelve-month free cash flow is deeply negative at -$190.0 million, with Q4 2025 operating cash flow at -$133.5 million. With only $203.8 million in cash, the company faces a near-term need for additional capital to fund operations despite revenue growth.
- Persistent Unprofitability: The company remains deeply unprofitable with a Q4 2025 net margin of -18.2% and a trailing net margin of -30.1%. The forward PE of 39.81x is a premium valuation that demands flawless execution on the path to profitability.
- Elevated Valuation Multiples: The trailing PS ratio of 13.63x and EV/Sales of 9.53x are elevated compared to the biotechnology industry, pricing in near-perfect commercial execution. Any slowdown in revenue growth or margin expansion could trigger significant multiple compression.
- High Stock-Specific Volatility: The stock's beta of -1.045 indicates it moves inversely and idiosyncratically to the broader market, driven by company-specific news. This is evidenced by a 52-week range from $271.96 to $615.00 and a recent 6-month decline of -14.63%, highlighting high volatility risk.
MDGL Technical Analysis
The stock is in a significant downtrend from its recent highs, trading near the lower end of its 52-week range. Over the past year, the stock is up 76.44%, but the 6-month change of -14.63% and the year-to-date decline of -17.01% highlight a substantial recent pullback. Currently priced at $492.83, it is trading approximately 36% above its 52-week low of $271.96 but 20% below its 52-week high of $615.00, indicating it has retreated meaningfully from its peak and is consolidating in a lower range. Recent momentum is weak and negative, with the stock down 1.92% over the past month and up 13.86% over the past 3 months; this 3-month positive return is overshadowed by a sharp decline from the $600+ levels seen in late December 2025, suggesting the short-term bounce is a relief rally within a broader corrective phase. Key technical support is the 52-week low area around $272, while resistance is at the recent highs near $615; a sustained break below $450 could signal a test of the $272 low, whereas reclaiming the $550-$570 zone is needed to suggest a trend reversal. The stock's beta of -1.045 indicates it has moved inversely to the broader market (SPY) over the measured period, exhibiting atypical, idiosyncratic volatility driven by company-specific news rather than market movements, which increases stock-specific risk.
Beta
-1.06
-1.06x market volatility
Max Drawdown
-29.4%
Largest decline past year
52-Week Range
$275-$615
Price range past year
Annual Return
+61.8%
Cumulative gain past year
| Period | MDGL Return | S&P 500 |
|---|---|---|
| 1m | -7.3% | -0.1% |
| 3m | +8.1% | +12.0% |
| 6m | -15.9% | +8.8% |
| 1y | +61.8% | +22.9% |
| ytd | -19.0% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MDGL Fundamental Analysis
Revenue is in its initial explosive growth phase following the commercial launch of Rezdiffra, with Q4 2025 revenue reaching $321.1 million, representing a year-over-year growth of 210.77% from the $103.3 million in Q4 2024. Sequential quarterly revenue has grown from $0 in Q1 2024 to $137.3 million in Q1 2025, $212.8 million in Q2 2025, $287.3 million in Q3 2025, and $321.1 million in Q4 2025, demonstrating a strong and accelerating commercial ramp. The company remains deeply unprofitable as it invests heavily in its launch, with a Q4 2025 net loss of $58.6 million and a net margin of -18.2%; however, gross margins are exceptionally high at 92.39%, typical for a pharmaceutical company. The loss has narrowed significantly from a net loss of $114.2 million in Q3 2025 and $151.97 million in Q2 2024, indicating improving operating leverage as revenue scales. The balance sheet shows a strong current ratio of 4.01 and a manageable debt-to-equity ratio of 0.59, but cash flow is a critical watch point: trailing twelve-month free cash flow is deeply negative at -$190.0 million, and operating cash flow for Q4 2025 was -$133.5 million. The company ended Q4 with $203.8 million in cash, and with substantial ongoing operating losses, the need for additional capital to fund operations remains a near-term financial risk despite the strong revenue trajectory.
Quarterly Revenue
$321083000.0B
2025-12
Revenue YoY Growth
+2.10%
YoY Comparison
Gross Margin
+0.92%
Latest Quarter
Free Cash Flow
$-190020000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MDGL Overvalued?
Given the company's negative net income, we lead with the Price-to-Sales (PS) ratio for valuation. The trailing PS ratio is 13.63x, while the forward-looking metric, EV/Sales, is 9.53x, indicating the market expects significant sales growth to justify the current market cap. The forward PE ratio of 39.81x, based on estimated future profitability, suggests the market is pricing in a rapid transition to earnings. Compared to the biotechnology industry, a PS ratio of 13.6x is elevated, reflecting a premium for Madrigal's first-mover advantage in the large, untapped MASH market and its current high-growth phase; this premium is directly tied to the success of the Rezdiffra launch. Historically, the stock's own PS ratio has compressed dramatically from over 400x in mid-2024 (pre-revenue) to the current 13.6x, reflecting the transition from a speculative, pre-commercial asset to a commercial-stage company. The current PS is near the lower end of its own historical range over the past two years, which primarily reflects the massive revenue infusion rather than multiple compression, and suggests the market is now valuing the stock more on near-term commercial execution than on long-dated pipeline optionality.
PE
-45.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -56x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-50.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on Madrigal's precarious cash position and deep unprofitability. With TTM free cash flow of -$190.0 million and only $203.8 million in cash, the company is burning cash at a rate that necessitates a capital raise within the next 12-18 months unless operating cash flow turns positive rapidly. The net margin of -30.1% and operating margin of -31.3% show the company remains far from self-sufficiency, and its entire financial model depends on the continued 200%+ revenue growth of a single product, Rezdiffra, creating extreme concentration risk.
Market & Competitive Risks are dominated by valuation compression. Trading at a PS ratio of 13.63x and a forward PE of 39.81x, the stock carries a significant premium that assumes flawless execution and multi-billion dollar peak sales. The stock's beta of -1.045 indicates it trades on idiosyncratic, company-specific news rather than market fundamentals, amplifying volatility. As a first-mover, the company faces imminent competitive threats from other late-stage MASH therapies, which could erode pricing power and market share, invalidating the current growth assumptions embedded in its valuation.
The Worst-Case Scenario involves a combination of slowing prescription growth for Rezdiffra, faster-than-expected competitive entry, and a failed capital raise in a tight credit environment. This could trigger a downward spiral of analyst downgrades, multiple compression from the current PS of 13.6x towards industry averages, and a liquidity crisis. The realistic downside would be a retest of the 52-week low of $271.96, representing a potential loss of approximately -45% from the current price of $492.83. A sustained break below key technical support near $450 could accelerate this move.
FAQ
The key risks are, in order of severity: 1) Financial Risk: Unsustainable cash burn (-$190M TTM FCF) necessitates a dilutive capital raise within 12-18 months. 2) Execution Risk: The entire company depends on one product, Rezdiffra; any slowdown in its launch cripples the thesis. 3) Competitive Risk: As the first-mover, it faces imminent threats from other late-stage MASH therapies that could erode its market share and pricing power. 4) Valuation Risk: The high PS ratio of 13.6x is vulnerable to compression if growth decelerates or profitability timelines are pushed out.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $500 and $600, as strong revenue growth continues but is offset by a capital raise. The Bull Case (25% probability) targets $615 to $700, driven by accelerating revenue and a path to cash flow positivity. The Bear Case (20% probability) warns of a drop to $272-$450 if growth stalls and dilution occurs. The Base Case is most likely, hinging on the assumption that Madrigal can secure funding without severely damaging shareholder value while maintaining robust prescription growth.
MDGL is fairly valued relative to its current hyper-growth phase but overvalued on a fundamental profitability basis. The trailing Price-to-Sales ratio of 13.63x is elevated compared to the biotech industry, reflecting a premium for its first-mover status and massive $4.97B forward revenue estimate. The forward PE of 39.81x prices in a rapid transition to earnings that is not yet proven. The valuation implies the market expects near-flawless commercial execution and minimal competitive disruption to justify its current price, leaving little room for error.
MDGL is a speculative buy only for investors with a very high risk tolerance and a long-term horizon. The bullish case, supported by 211% YoY revenue growth and first-mover advantage, offers significant upside to analyst targets. However, the critical -$190M annual cash burn against a $204M cash balance creates a high probability of near-term dilution, capping upside. It could be a good buy for aggressive growth portfolios after a significant pullback towards the $400-$450 level, which would offer a better margin of safety against the financing overhang.
MDGL is strictly a long-term investment with a suggested minimum holding period of 3-5 years. The company is in the early stages of commercializing its first product, and the path to sustained profitability and free cash flow generation will take multiple years. The stock's high volatility (beta of -1.045) and sensitivity to quarterly prescription data make it unsuitable for short-term trading. Long-term investors are betting on Rezdiffra achieving multi-billion dollar peak sales, which will require patience through inevitable quarterly volatility, competitive news, and likely dilution events.